EVH · Evolent Health, Inc.
AI read · Good for EVH
The AI's read
The upgrade reflects a more favorable view of Evolent's shares. The unchanged target tempers that message, but the rating change is still the clearest new company-specific signal.
Truist moved Evolent's rating from Hold to Buy, a favorable sign. It kept its $6-per-share target unchanged, which tempers the upgrade.
The upgrade reflects a more favorable view of Evolent's shares. The unchanged target tempers that message, but the rating change is still the clearest new company-specific signal.
Follow Evolent Health, Inc. (EVH) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for EVH